InMed Pharmaceuticals (INM) Net Equity Issued and Repurchased (2021 - 2023)
InMed Pharmaceuticals (INM) posted quarterly Net Equity Issued and Repurchased of $174.0 for Q1 2023, down 100.0% quarter-over-quarter from $6.0 million in Q4 2022.
InMed Pharmaceuticals (INM) Net Equity Issued and Repurchased (2021 - 2023) Analysis & Trends
InMed Pharmaceuticals' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $174.0 for Q1 2023.
- In Q1 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $174.0; the TTM figure through Jun 2023 stood at $12.0 million (down 30.01% YoY), while the FY2023 annual figure was $12.0 million, down 30.01% from the prior year.
- Net Equity Issued and Repurchased for Q1 2023 stood at $174.0, down from $6.0 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $12.0 million in Q3 2021, with the low at $174.0 in Q1 2023.
- The 3-year median for Net Equity Issued and Repurchased is $5.1 million (2022), against an average of $4.8 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 3408932.39% in 2022, while the deepest fall reached 50.0% in 2022.
- InMed Pharmaceuticals' Net Equity Issued and Repurchased stood at $176.0 in 2021, then surged by 3408932.39% to $6.0 million in 2022, then plunged by 100.0% to $174.0 in 2023.
- Business Quant data shows INM's Net Equity Issued and Repurchased at $174.0 in Q1 2023, $6.0 million in Q4 2022, and $6.0 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 174.00 |
| Mar 31, 2023 | 174.00 |
| Dec 31, 2022 | 6.00 Mn |
| Dec 31, 2022 | 6.00 Mn |
| Sep 30, 2022 | 6.00 Mn |
| Sep 30, 2022 | 6.00 Mn |
| Jun 30, 2022 | 5.15 Mn |
| Jun 30, 2022 | 5.15 Mn |
| Dec 31, 2021 | 176.00 |
| Dec 31, 2021 | 176.00 |
| Sep 30, 2021 | 12.00 Mn |
| Sep 30, 2021 | 12.00 Mn |
| Mar 31, 2021 | 4.46 Mn |
| Mar 31, 2021 | 4.46 Mn |